Debt-to-equity of Entrada Therapeutics, Inc. from 30 Jun 2022 to 30 Sep 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Entrada Therapeutics, Inc. quarterly Debt-to-equity in % history and change rate from 30 Jun 2022 to 30 Sep 2025.
  • Entrada Therapeutics, Inc. Debt-to-equity for the quarter ending 30 Sep 2025 was 20%, a 64% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Entrada Therapeutics, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 20% -35% -64% 30 Sep 2025
Q2 2025 22% -50% -69% 30 Jun 2025
Q1 2025 27% -76% -74% 31 Mar 2025
Q4 2024 40% -68% -63% 31 Dec 2024
Q3 2024 55% -35% -39% 30 Sep 2024
Q2 2024 72% +3% +3.9% 30 Jun 2024
Q1 2024 103% +64% +162% 31 Mar 2024
Q4 2023 108% +92% +560% 31 Dec 2023
Q3 2023 91% +79% +656% 30 Sep 2023
Q2 2023 70% +57% +463% 30 Jun 2023
Q1 2023 39% 31 Mar 2023
Q4 2022 16% 31 Dec 2022
Q3 2022 12% 30 Sep 2022
Q2 2022 12% 30 Jun 2022
* An asterisk sign (*) next to the value indicates that the value is likely invalid.